Jim Cramer knocks down a new analyst sell rating on a medtech stock as shortsighted
Related
Healthy Returns: RFK Jr.’s Covid vaccine recommendation chan...
1 month ago
168
UnitedHealth Group shares plunge 18% on reported DOJ probe i...
1 month ago
221
Kennedy sidesteps vaccine questions: ‘I don’t think people s...
1 month ago
188
Hims & Hers gives weak outlook but says more collaborations ...
1 month ago
260
Eli Lilly sales soar 45% on weight loss drug demand, but dru...
1 month ago
197
Oracle engineers caused days-long software outage at U.S. ho...
2 months ago
200
23andMe bankruptcy: With America's DNA put on sale, market p...
2 months ago
257
Life science stocks are under pressure due to possible NIH f...
3 months ago
215
Bristol Myers' stock decline in response to weak guidance is...
4 months ago
240
Eli Lilly posts mixed quarter even as demand for weight loss...
4 months ago
204
23andMe is exploring strategic alternatives, looking to rais...
4 months ago
224
We're lightening up on a rallying stock that's grown too big...
4 months ago
205
Our newest portfolio stock backed off its recent 52-week hig...
6 months ago
241
Prostavive Reviews: Top Benefits, Natural Solution and How P...
7 months ago
739
Trump says RFK Jr. plan to remove fluoride from public water...
7 months ago
248
CVS to replace CEO Karen Lynch with exec David Joyner as pro...
8 months ago
272
This government-backed startup is growing blood to help figh...
9 months ago
280
4 ways how cancer care has improved in India
1 year ago
400
Trending
Popular
Who is Shefali Jariwala's husband Parag Tyagi?
1 day ago
295
BTS' V to appear in ‘Squid Game Season 3’?
2 days ago
267
Squid Game 3: When and where to watch in India
2 days ago
141
© Rclipse.Com 2025. All rights are reserved